Results 1 to 10 of about 295 (110)
Developing a vaccine for type 1 diabetes by targeting coxsackievirus B [PDF]
Expert Review of Vaccines, 2018 Introduction: Virus infections have long been considered as a possible cause of type 1 diabetes (T1D). One virus group, enteroviruses (EVs), has been studied extensively, and clinical development of a vaccine against T1D-associated EV types has started ...
Heikki Hyoty, Mikael Knip
exaly +4 more sources
Antiviral Effects of Menthol on Coxsackievirus B
Viruses, 2020 Coxsackievirus B (CVB) is a common human enterovirus that causes systemic infection but specifically replicates to high titers in the pancreas. It was reported that certain viruses induce mitochondrial fission to support infection. We documented that CVB
David J.R. Taylor +10 more
doaj +3 more sources
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges [PDF]
Viruses, 2021 Oncolytic viruses have emerged as a promising strategy for cancer therapy due to their dual ability to selectively infect and lyse tumor cells and to induce systemic anti-tumor immunity. Among various candidate viruses, coxsackievirus group B (CVBs) have
Huitao Liu, Honglin Luo
doaj +3 more sources
Immune mechanisms of group B coxsackievirus induced viral myocarditis
Virulence, 2023 Viral myocarditis is known to be a primary cause of dilated cardiomyopathy (DCM) that can lead to heart failure and sudden cardiac death and is invariably caused by myocardial viral infection following active inflammatory destruction of the myocardium ...
Yue Zhang +4 more
doaj +3 more sources
ASSOCIATION OF ANTI-COXSACKIE VIRUS-B IgG WITH AUTOANTIBODIES RELATED TO TYPE 1 DIABETES MELLITUS
The Iraqi Journal of Medical Sciences, 2022 Background: Coxsackievirus B is a virus may cause type 1 diabetes. There are links between Coxsackievirus B infections and type 1 diabetes. The presence of autoantibodies in pancreatic beta cells has been linked to the development of type 1 ...
Hakeem Gh. Hassan +2 more
doaj +9 more sources
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells
Molecular Therapy: Oncolytics, 2023 Primary drug resistance and minimal residual disease are major challenges in the treatment of B cell neoplasms. Therefore, this study aimed to identify a novel treatment capable of eradicating malignant B cells and drug-resistant disease.
Matthew Holmes +12 more
doaj +1 more source
Viruses, 2020 Coxsackievirus group B (CVB) contains six serotypes that can affect various organs. Some of these organ-specific diseases such as myocarditis and pancreatitis can be caused by more than one serotype.
Ninaad Lasrado +8 more
doaj +1 more source
The Role of B Lymphocytes in Coxsackievirus B3 Infection [PDF]
The American Journal of Pathology, 1999 Coxsackieviruses are important human pathogens, frequently causing myocarditis, pancreatitis, and a variety of less severe diseases. B lymphocytes appear central to the interaction between these viruses and their mammalian hosts, because agammaglobulinemic humans, genetically incapable of antibody production, are susceptible to chronic infections by ...
I, Mena +5 more
openaire +2 more sources
QSAR studies of BBR analogues against coxsackievirus B1
Bulletin of the National Research Centre, 2022 Background Coxsackievirus group B (CVBs) are common enteroviruses associated with several diseases from etiologically to inflammatory cardiomyopathies and constitute a severe cause of mortality in newborn resulting in severe meningitis, fulminant ...
Babatunde Samuel Obadawo +2 more
doaj +1 more source
Pharmaceuticals, 2023 Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market ...
Chiara Tammaro +5 more
doaj +1 more source